IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis.
about
Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritisDrug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumabPredictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.Hypomethylation of interleukin 6 correlates with renal involvement in systemic lupus erythematosus.Circulating interleukin-6 and rheumatoid arthritis: A Mendelian randomization meta-analysis.The effects of gene polymorphisms in interleukin-4 and interleukin-6 on the susceptibility of rheumatoid arthritis in a Chinese population.Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.Rheumatoid arthritis: a case for personalized health care?Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Molecular modeling and SPRi investigations of interleukin 6 (IL6) protein and DNA aptamers.Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.
P2860
Q27022559-839B725B-7082-4413-88FF-0C27BD90A1B4Q27023091-E7F5B1AE-A23E-4B4E-BD9A-F1A60A7C6D24Q27692641-D01CFD16-6702-43A3-BFA1-1E6D67CDF7E7Q35631910-6696A47B-509A-4688-A06C-E400F1E5B328Q37003697-1A02BFE2-4100-4B1C-848C-F1DC43ABC1C2Q37636112-5B0C8485-E5EA-4B27-877D-4447033131ECQ38164315-FDC48984-28F6-40BB-8C42-EA6E18574339Q38182471-C5B66AF3-903F-4E6A-ABF8-8B7829E8679CQ38259809-33B61AF4-FB51-44AA-8E8C-7C16427F7A72Q38285827-70EB5CD8-E359-4863-9255-C194F6118A67Q40423985-17B69039-154D-488C-AF30-703BC5FC52D0Q42633541-8E3E26BA-DF8B-43DE-965A-B81A67324D19Q50954695-F85E2F67-BA59-4170-BF41-78043271BF55Q51627957-A4B31B77-0B28-4F0E-8F45-37F0331055D6
P2860
IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@en
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@nl
type
label
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@en
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@nl
prefLabel
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@en
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@nl
P2093
P2860
P1433
P1476
IL-6 pathway-driven investigat ...... ition in rheumatoid arthritis.
@en
P2093
Adam Platt
Andrew Hemmings
Andrew Kenwright
Christina Rabe
Guiyuan Lei
Jianmei Wang
Mitchell Martin
Olivier Harari
Ruchi Upmanyu
Ryma Benayed
P2860
P304
P356
10.1136/BMJOPEN-2013-003199
P577
2013-08-19T00:00:00Z